Nova Eye Medical Limited (ASX: EYE) - Share Price
Current share price for EYE : $0.145 0.005 (3.33%)+
Nova Eye Medical Limited (EYE) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack and Molteno3. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are in Fremont, California and Dunedin, New Zealand.
EYE General Information +
| ASX Code | EYE |
| Website | http://www.nova-eye.com |
| Industry/Sector | Health Care Equipment |
| Market Cap ($M) | 41 |
| EYE Share Price | $0.145 |
| Day High | $0.145 |
| Day Low | $0.145 |
| Last Close | $0.150 |
| EYE Share Price Movement | $0.01 ( 3.33% ) |
Prices as at 10:21, 30 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Nova Eye Medical Limited (EYE) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Result | 13.5¢ | 100% | 21 Jul 2020 | 29 Jul 2020 | - | - | - |
See all dividends from Nova Eye Medical Limited (EYE) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Nova Eye Medical Limited (EYE) price-sensitive announcements
EYE - Quarterly Activities/Appendix 4C Cash Flow Report
Nova Eye Medical Limited (ASX: EYE) reported in its Quarterly Activities and Appendix 4C C
Nova Eye Medical Limited (EYE)
27 Oct 2026 | 12:59 PM
27 Oct 2026 | 12:59 PM
EYE - Full Year Financial Results
Nova Eye Medical Limited reported a 26% increase in full-year sales to A$34.9 million for
Nova Eye Medical Limited (EYE)
26 Aug 2026 | 5:04 PM
26 Aug 2026 | 5:04 PM
EYE - Appendix 4E and Annual Report
The document is the Annual Report and Appendix 4E for Nova Eye Medical Limited for the fin
Nova Eye Medical Limited (EYE)
26 Aug 2026 | 4:55 PM
26 Aug 2026 | 4:55 PM
EYE - Quarterly Activities/Appendix 4C Cash Flow Report
Nova Eye Medical Limited reported a strong performance for the year ending 30 June 2026, a
Nova Eye Medical Limited (EYE)
29 Jul 2026 | 11:03 AM
29 Jul 2026 | 11:03 AM
Nova Eye Medical Limited (EYE) Recent ASX Announcements
EYE Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$4.33 | -$1.50 | -58.50% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$9.06 | -$3.70 | -15.10% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$8.79 | -$4.30 | -25.30% | 0.00 | 0.00 | 0.00% | 0.0% |
EYE Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Cochlear Limited (COH) | $9,156M | -0.3136 | 0.2540 | 0.0785 | 34.0840 | 27.1802 | 25.2021 | 2.46% | 2.56% | 2.79% |
| Nova Eye Medical Limited (EYE) | $43M | -0.5847 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Fisher & Paykel Healthcare Corporation Limited (FPH) | $22,248M | 0.1388 | 0.1452 | 0.1573 | 57.1904 | 49.9406 | 43.1538 | 1.15% | 1.24% | 1.38% |
| Imricor Medical Systems Inc (IMR) | $481M | -0.4254 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| ResMed Inc. (RMD) | $20,029M | 9.5922 | 0.1012 | 0.0991 | 22.8102 | 20.7147 | 18.8476 | 1.02% | 1.11% | 1.20% |
EYE Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 2.99 | 0.00 |
| Market | 0.30 | 13.20 | 1.03 | 0.74 |
| Sector | 0.72 | 21.80 | 1.76 | 2.45 |
EYE Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Victor Previn | Executive Director, Executive Chairman | 16 Jul 2001 |
| Mr Thomas (Tom) Anthony Spurling | Managing Director | 29 Aug 2020 |
| Mr Rahmon Coupe | Non-Executive Director | 15 May 2013 |
| Mr Daniel Webb | Non-Executive Director | 17 Nov 2022 |
Nova Eye Medical Limited (EYE) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 27 Aug 2026 | SPURLING, Thomas (Tom) | Buy | Direct Shares | 43,493 | $0.150 | $6,523.950 |
| 27 Aug 2026 | SPURLING, Thomas (Tom) | Buy | Direct Shares | 116,507 | $0.145 | $16,893.515 |
| 1 Sep 2025 | SPURLING, Thomas (Tom) | Buy | Direct Shares | 78,273 | $0.150 | $11,740.950 |
See all changes in directors' interest & trades for Nova Eye Medical Limited (EYE) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
EYE Management
| Name | Position |
|---|---|
| Simon Ramsey Alexander Gray | Company Secretary |
EYE Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Nova Eye Medical Limited (EYE). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 50,518,953 (17.73%) | HSBC Custody Nominees (Australia) Limited |
EYE Calendar of Events
| Date | Event |
|---|---|
| 25 August 2027 | Report (Annual) |
| 25 August 2027 | Report (Prelim) |
| 25 February 2027 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
